Nuo Therapeutics Closes $325,000 Second Funding Under Amended Loan; Total Draw Reaches $2 Million
Nuo Therapeutics (AURX) closed a $325,000 second funding round, issuing 12% secured notes due 2028 and warrants. Total proceeds under the facility reached $2,000,000. The amendment allowed four new lenders, including a director, to join without increasing warrant coverage. The funds were secured to accelerate the second closing date and add lenders for liquidity.
How this was made
The 30-second read
Why it matters
The $2 million facility provides short‑term liquidity but is modest for a public biotech.
Market read
Micro‑cap financing event with limited immediate trading relevance.
What to watch
Potential future warrants could dilute existing shareholders if exercised.
Background
Nuo Therapeutics filed an 8‑K reporting an amendment to its loan agreement and a second funding tranche.
Ticker impact
Nuo Therapeutics closed a $325,000 second funding, bringing total loan proceeds to $2 million.
likely modest upward pressure as the market prices in the added liquidity.
Micro‑cap capital raises of this size rarely move the stock significantly, but the fresh cash may support short‑term buying.
Market effects
Limited; only affects niche biotech financing trends.
None; the raise is company‑specific.
Minimal; no broader market effect.
Counterpoint
Investors may view the raise as a sign of cash‑flow strain, prompting short positions.
Key entities
- companyNuo Therapeutics, Inc.
Biotech firm raising capital via secured promissory notes.